Photographer: Caitlin O'Hara/Bloomberg via Getty ImagesIf you listen to third-quarter corporate earnings calls, it might seem like everyone is taking weight-loss drugs. Delta Air Lines , PepsiCo , Philip Morris International and Darden Restaurants are just some of the companies that faced questions from analysts about how the drugs are affecting their bottom lines. While some analysts are making sweeping claims about how obesity drugs will reshape the industries they cover, the medicines are still in the early days. Known as GLP-1s, the drugs were first approved for diabetes and are now also being used for obesity. But even so, only a sliver of eligible people are actually taking the drugs at this point, said Goldman Sachs analyst Chris Shibutani.

---

Persons: Caitlin O'Hara, Philip Morris, it's, Nestle –, It's, Wegovy, Goldman Sachs, Chris Shibutani Organizations: PepsiCo Inc, Bloomberg, Getty, Delta Air Lines, PepsiCo, Philip, Philip Morris International, Darden, Hershey, Conagra, Nestle, Novo Nordisk Locations: Phoenix , Arizona, U.S, Novo